Biomarker analysis from the phase 3 CheckMate 9ER trial of nivolumab + cabozantinib v sunitinib for advanced renal cell carcinoma (aRCC) Meeting Abstract
| Authors: | Choueiri, T. K.; Motzer, R. J.; Powles, T.; Burotto, M.; Apolo, A. B.; Escudier, B.; Tomita, Y.; McDermott, D. F.; Braun, D. A.; Han, C.; Lee, G.; Dwivedi, B.; Vemula, S. V.; Li, J.; Fedorov, V.; Gupta, S. |
| Abstract Title: | Biomarker analysis from the phase 3 CheckMate 9ER trial of nivolumab + cabozantinib v sunitinib for advanced renal cell carcinoma (aRCC) |
| Meeting Title: | 2023 ASCO Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2023 Feb 16-18 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-02-20 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.6_suppl.608 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting abstract: 608 -- Accession Number: 162006841 -- Entry Date: In Process -- Revision Date: 20230223 -- Publication Type: Article -- Supplement Title: 2/21/2023 Supplement -- Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA -- NLM UID: 8309333. -- Source: Cinahl |
Altmetric
Citation Impact
BMJ Impact Analytics
